Oslo, Norway, 29 April 2020 – Targovax ASA (OSE: TRVX) will announce its first quarter 2020 results on Thursday 7 May 2020. An online presentation by Targovax’s management to investors, analysts and the press will take place at 10:00 CET.
The results report and the presentation will be available at www.targovax.com in the Investors section from 07:00 CET.
As a consequence of the Corona situation, there will not be a physical presentation of the results. Instead, we invite to a live webcast 7 May at 10.00 CET. You can join the webcast here. It will be possible to ask questions during the presentation.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Media and IR enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors. Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer.
ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal malignancies and has already shown promising clinical results both as monotherapy and in combination with chemotherapy, and a checkpoint inhibitor.